Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutropenia in Women With Breast Cancer in China: Results Based on Real-World Data
Background: Pegylated recombinant human granulocyte colony-stimulating factors (PEG-rhG-CSFs) are more commonly and widely used than recombinant human granulocyte colony-stimulating factors (rhG-CSFs) in preventing chemotherapy-induced neutropenia in patients with stage II-IV breast cancer. To reduc...
Saved in:
Main Authors: | Jie Zhao (Author), Gaoxing Qiao (Author), Yan Liang (Author), Jia Li (Author), Wei Hu (Author), Xu Zuo (Author), Junfang Li (Author), Chenglong Zhao (Author), Xiaojian Zhang (Author), Shuzhang Du (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bioassay of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) for Neutropenia Treatment in Male Sprague Dawley Rats
by: Riyona Desvy Pratiwi, et al.
Published: (2020) -
Efficacy, safety, and cost-effectiveness of pegylated PEG-rhg-CSF in pediatric patients receiving high-intensity chemotherapy: results from a phase II study
by: Junting Huang, et al.
Published: (2024) -
Using recombinant human G-CSF to treat chemotherapy-induced neutropenia over 3 decades: What is next?
by: Jason Xu, et al.
Published: (2023) -
Efficacy of Low-Dose rhGM-CSF Treatment in a Patient With Severe Congenital Neutropenia Due to CSF3R Deficiency: Case Report of a Novel Biallelic CSF3R Mutation and Literature Review
by: Junli Zhou, et al.
Published: (2021) -
Chemotherapy adjuvant and chemotherapy-induced neutropenia
by: Yiu-Tai Li, et al.
Published: (2022)